358 related articles for article (PubMed ID: 22876886)
21. The thioredoxin system and cancer therapy: a review.
Mohammadi F; Soltani A; Ghahremanloo A; Javid H; Hashemy SI
Cancer Chemother Pharmacol; 2019 Nov; 84(5):925-935. PubMed ID: 31367788
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
[TBL] [Abstract][Full Text] [Related]
23. Lichen Acids May Be Used as A Potential Drug For Cancer Therapy; by Inhibiting Mitochondrial Thioredoxin Reductase Purified From Rat Lung.
Ozgencli I; Budak H; Ciftci M; Anar M
Anticancer Agents Med Chem; 2018; 18(11):1599-1605. PubMed ID: 29793415
[TBL] [Abstract][Full Text] [Related]
24. Selenocysteine in mammalian thioredoxin reductase and application of ebselen as a therapeutic.
Ren X; Zou L; Lu J; Holmgren A
Free Radic Biol Med; 2018 Nov; 127():238-247. PubMed ID: 29807162
[TBL] [Abstract][Full Text] [Related]
25. Thioredoxin reductase inhibitors: updated patent review (2017-present).
Chupakhin E; Krasavin M
Expert Opin Ther Pat; 2021 Aug; 31(8):745-758. PubMed ID: 33666133
[No Abstract] [Full Text] [Related]
26. On the potential of thioredoxin reductase inhibitors for cancer therapy.
Urig S; Becker K
Semin Cancer Biol; 2006 Dec; 16(6):452-65. PubMed ID: 17056271
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex.
Arnér ES; Nakamura H; Sasada T; Yodoi J; Holmgren A; Spyrou G
Free Radic Biol Med; 2001 Nov; 31(10):1170-8. PubMed ID: 11705695
[TBL] [Abstract][Full Text] [Related]
28. Thioredoxin reductase-thioredoxin fusion enzyme from Mycobacterium leprae: comparison with the separately expressed thioredoxin reductase.
Wang PF; Marcinkeviciene J; Williams CH; Blanchard JS
Biochemistry; 1998 Nov; 37(46):16378-89. PubMed ID: 9819230
[TBL] [Abstract][Full Text] [Related]
29. Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenes.
Liu X; Pietsch KE; Sturla SJ
Chem Res Toxicol; 2011 May; 24(5):726-36. PubMed ID: 21443269
[TBL] [Abstract][Full Text] [Related]
30. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II).
Sasada T; Nakamura H; Ueda S; Sato N; Kitaoka Y; Gon Y; Takabayashi A; Spyrou G; Holmgren A; Yodoi J
Free Radic Biol Med; 1999 Sep; 27(5-6):504-14. PubMed ID: 10490269
[TBL] [Abstract][Full Text] [Related]
31. Crystal structure of the Plasmodium falciparum thioredoxin reductase-thioredoxin complex.
Fritz-Wolf K; Jortzik E; Stumpf M; Preuss J; Iozef R; Rahlfs S; Becker K
J Mol Biol; 2013 Sep; 425(18):3446-60. PubMed ID: 23845423
[TBL] [Abstract][Full Text] [Related]
32. Thioredoxin system in cell death progression.
Lu J; Holmgren A
Antioxid Redox Signal; 2012 Dec; 17(12):1738-47. PubMed ID: 22530689
[TBL] [Abstract][Full Text] [Related]
33. Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads.
Kaminska KK; Bertrand HC; Tajima H; Stafford WC; Cheng Q; Chen W; Wells G; Arner ES; Chew EH
Oncotarget; 2016 Jun; 7(26):40233-40251. PubMed ID: 27244886
[TBL] [Abstract][Full Text] [Related]
34. Thioredoxin reductase as a pharmacological target.
Bjørklund G; Zou L; Wang J; Chasapis CT; Peana M
Pharmacol Res; 2021 Dec; 174():105854. PubMed ID: 34455077
[TBL] [Abstract][Full Text] [Related]
35. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo.
Wang X; Zhang J; Xu T
Toxicol Appl Pharmacol; 2007 Jan; 218(1):88-95. PubMed ID: 17156807
[TBL] [Abstract][Full Text] [Related]
36. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase.
Gandin V; Fernandes AP; Rigobello MP; Dani B; Sorrentino F; Tisato F; Björnstedt M; Bindoli A; Sturaro A; Rella R; Marzano C
Biochem Pharmacol; 2010 Jan; 79(2):90-101. PubMed ID: 19665452
[TBL] [Abstract][Full Text] [Related]
37. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase.
Hashemy SI; Ungerstedt JS; Zahedi Avval F; Holmgren A
J Biol Chem; 2006 Apr; 281(16):10691-7. PubMed ID: 16481328
[TBL] [Abstract][Full Text] [Related]
38. Potential Anticancer Activity of Auranofin.
Onodera T; Momose I; Kawada M
Chem Pharm Bull (Tokyo); 2019; 67(3):186-191. PubMed ID: 30827998
[TBL] [Abstract][Full Text] [Related]
39. Noble metal targeting of thioredoxin reductase--covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin.
Prast-Nielsen S; Cebula M; Pader I; Arnér ES
Free Radic Biol Med; 2010 Dec; 49(11):1765-78. PubMed ID: 20851179
[TBL] [Abstract][Full Text] [Related]
40. Mechanism-based inactivation of thioredoxin reductase from Plasmodium falciparum by Mannich bases. Implication for cytotoxicity.
Davioud-Charvet E; McLeish MJ; Veine DM; Giegel D; Arscott LD; Andricopulo AD; Becker K; Müller S; Schirmer RH; Williams CH; Kenyon GL
Biochemistry; 2003 Nov; 42(45):13319-30. PubMed ID: 14609342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
